Background/Objectives: Lymph node (LN) assessment for cases of endometrial intraepithelial neoplasia (EIN), a known precursor to endometrial cancer (EC), is a topic of debate. Some experts believe this practice could avoid re-staging of disease and influence the decision to administer adjuvant treatment. However, it is known that obtaining sentinel lymph node (SLN) biopsies in patients with an elevated body mass index (BMI) can be more challenging. We thus sought to evaluate the effect of BMI on the SLN detection rate (DR) during robotic hysterectomy in EIN cases. Methods: We conducted a retrospective chart review for patients with a pre-operative diagnosis of EIN who underwent robotic hysterectomy with SLN sampling. Five BMI categories were determined according to the literature. Distribution normality was assessed with the Kolmogorov–Smirnov test. Continuous variables, non-parametric continuous variables and categorical variables were assessed with the appropriate statistical tests (two-tailed Student’s t-tests, Mann–Whitney U-tests, and chi-squared tests, respectively). Results: 115 patients were included (average BMI of 34.75 ± 9.38 SD). The bilateral SLN DR was not significantly different between BMI groups (p = 0.606). The difference in unilateral SLN DR between BMI groups was also non-significant (p = 0.269). When examining high BMI subgroups (BMI > 30 and BMI > 40), no significant difference was found in bilateral nor unilateral SLN DR. A logistic regression model showed that for every unit of BMI, the likelihood of SLN DR did not change significantly. Conclusions: We found no connection between obesity (BMI > 30) or morbid obesity (BMI > 40) and reduced SLN DR in EIN cases, nor a significant variation in the DR when comparing all the different BMI subgroups.
Misoprostol treatment for early pregnancy loss has varied success demonstrated in previous studies. Incorporating predictors in a single clinical scoring system would be highly beneficial in clinical practice. To develop and evaluate the accuracy of a scoring system to predict misoprostol treatment outcomes for managing early pregnancy loss. Retrospective cohort and validation study. Patients discharged from the gynecologic emergency department from 2013 to 2016, diagnosed with early pregnancy loss, who were treated with 800 mcg misoprostol, administrated vaginally were included. All were sonographically reevaluated within 48–72 hours. Patients in whom the gestational sac was not expelled or with endometrial lining >30 mm were offered a repeat dose and returned for reevaluation after seven days. A successful response was defined as complete expulsion. Clinical data were reviewed to identify predictors for successful responses. The scoring system was then retrospectively evaluated on a second cohort to evaluate its accuracy. Multivariate logistic regression was performed to identify factors most predictive of treatment response. The development cohort included 126 patients. Six factors were found to be most predictive of misoprostol treatment effectiveness: nulliparity, prior complete spontaneous abortion, gestational age, vaginal bleeding, abdominal pain, and mean sac diameter, yielding a score of 0–8 (the MISOPRED score), where 8 represents the highest-likelihood of success. The score was validated retrospectively with 119 participants. Successful response in the group with the lowest likelihood score (score 0–3) was 9%, compared with 82% in the highest likelihood score group (score 7–8). Using the MISOPRED score, approximately 15% of patients previously planned to receive misoprostol treatment can be referred for surgical management. MISOPRED score can be utilized as an adjunct tool for clinical decision-making in cases of Early pregnancy loss. To our knowledge, this is the first scoring system suggested to predict the success rate in these cases.
5 April 2024 in Journal of the National Comprehensive Cancer Network
"BPI24-011: Impact of Obesity on Sentinel Lymph Node Mapping in Patients With Endometrial Intraepithelial Neoplasia Undergoing Robotic Surgery" published on 05 Apr 2024 by National Comprehensive Cancer Network.
Background: High-grade endometrial stromal sarcoma (HGESS) is a rare and aggressive uterine mesenchymal tumor with a significant potential for recurrence and metastasis. Advances in molecular pathology have identified recurrent gene fusions involving the neurotrophic tyrosine receptor kinase (NTRK) genes, which are crucial for tumorigenesis. The identification of NTRK fusions has significant therapeutic implications, as targeted therapies such as Larotrectinib, a selective tyrosine receptor kinase (TRK) inhibitor, have demonstrated remarkable efficacy in NTRK fusion-positive tumors across various tumor histologies. Case Presentation: This report depicts the case of a 42-year-old woman with HGESS harboring an NTRK fusion diagnosed by histopathology and immunohistochemistry after undergoing a vaginal myomectomy. She subsequently underwent a robotic total hysterectomy, bilateral salpingo-oophorectomy, and bilateral lymph node dissection. Following a four-year disease-free interval, HGESS relapsed. The patient received three cycles of gemcitabine plus docetaxel. Subsequent CT imaging indicated progression of the pelvic mass. Molecular testing identified an NTRK fusion. Accordingly, larotrectinib was initiated in the setting of progressive disease. After three months, imaging demonstrated a significant decrease in the pelvic mass and near-complete radiographic resolution of the pulmonary nodules. The patient remained on larotrectinib, with January 2024 imaging showing no evidence of recurrence. Conclusions: The case presented highlights a personalized approach based on molecular profiling, and the successful use of larotrectinib, a TRK inhibitor, after the identification of an NTRK fusion-positive HGESS, emphasizing the importance of molecular diagnostics and targeted therapy in managing this rare malignancy.